Войти в систему Зарегистрироваться бесплатно

Adma Biologics Inc Долг / собственный капитал

Что обозначает Долг / собственный капитал в Adma Biologics Inc?

Долг / собственный капитал Adma Biologics Inc является 1.43

Какое определение для Долг / собственный капитал?



Соотношение долга к собственному капиталу - это финансовое соотношение, показывающее относительную пропорцию собственного капитала и долга, используемых для финансирования активов компании.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Долг / собственный капитал компаний в Health Care сектор на NASDAQ по сравнению с Adma Biologics Inc

Что делает Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Компании с долг / собственный капитал похож на Adma Biologics Inc